The diagnostic concept of schizophrenia: its history, evolution, and future prospects by Jablensky, Assen
o the best of present knowledge, schizophrenia
is a disorder with variable phenotypic expression and
poorly understood, complex etiology, involving a major
genetic contribution, as well as environmental factors
interacting with the genetic susceptibility. Multiple genes
and different combinations of their polymorphic variants
provide the genetic background, with a proportion of the
transmitted genotypes remaining clinically unexpressed.
Schizophrenia occurs in diverse populations at compa-
rable rates,
1 which is consistent with an ancient origin
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More than a century since the delineation of dementia praecox by Kraepelin, the etiology, neuropathology, and patho-
physiology of schizophrenia remain elusive. Despite the availability of criteria allowing reliable diagnostic identifica-
tion, schizophrenia essentially remains a broad clinical syndrome defined by reported subjective experiences (symptoms),
loss of function (behavioral impairments), and variable patterns of course. Research has identified a number of puta-
tive biological markers associated with the disorder, including neurocognitive dysfunction, brain dysmorphology, and
neurochemical abnormalities. Yet none of these variables has to date been definitively proven to possess the sensitiv-
ity and specificity expected of a diagnostic test. Genetic linkage and association studies have targeted multiple candi-
date loci and genes, but failed to demonstrate that any specific gene variant, or a combination of genes, is either nec-
essary or sufficient to cause schizophrenia. Thus, the existence of a specific brain disease underlying schizophrenia remains
a hypothesis. Against a background of an ever-increasing volume of research data, the inconclusiveness of the search
for causes of the disorder fuels doubts about the validity of the schizophrenia construct as presently defined. Given the
protean nature of the symptoms of schizophrenia and the poor coherence of the clinical and biological findings, such
doubts are not without reason. However, simply dismantling the concept is unlikely to result in an alternative model
that would account for the host of clinical phenomena and research data consistent with a disease hypothesis of schiz-
ophrenia. For the time being, the clinical concept of schizophrenia is supported by empirical evidence that its multiple
facets form a broad syndrome with non-negligible internal cohesion and a characteristic evolution over time. The dis-
section of the syndrome with the aid of endophenotypes is beginning to be perceived as a promising approach in schiz-
ophrenia genetics.  
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PAGES_DCNS 46_5.qxd:DCNS#45  9/09/10  9:39  Page 271and—as far as records go—its incidence has not changed
much over the past two centuries.
Diagnostic concepts play a critical role in the manage-
ment and treatment of schizophrenia patients; in
research aiming to identify risk factors and causal mech-
anisms, as well as in attempts to resolve contentious
issues, such as comorbidity and relationships among
proximal or partly overlapping disorders. A principal
source of difficulty in this endeavor is the complex
nature of the disorder itself, and the inherent weakness
of the diagnostic concept of schizophrenia, in that it
remains based upon assumptions about an underlying
but still unknown disease process. Most of the attributes
defining schizophrenia are primarily inferential and
depend on self-reported subjective experience. The
underlying structural and functional pathology is insuf-
ficiently understood, and there is no objective diagnos-
tic test or validated biological marker that could provide
a secure anchor for either clinical decision-making or
biological and epidemiological research. Recurrent con-
troversies in schizophrenia research concern its delimi-
tation from other psychoses, bipolar affective disorder,
and neurodevelopmental disorders; the validity of the
schizophrenia spectrum concept and the existence of
subclinical forms, such as schizotypal disorder; the util-
ity of its categorical classification as compared with
descriptive symptom dimensions or subtypes based on
quantitative cognitive traits,
2 and the discordances
between the ICD-10 and DSM-IV criteria for its diag-
nosis. The aim of the present paper is to highlight aspects
of the origin, evolution, and current state of the diag-
nostic concept of schizophrenia—ending with a specu-
lation about its future prospects.
A brief overview of the history of the concept
Kraepelin and the construction of dementia praecox
The disease concept of schizophrenia is of a relatively
recent origin, as compared with disorders such as melan-
cholia, mania, or generic “insanity,” all known since
antiquity. By the middle of the 19th century, European
psychiatrists began describing disorders of unknown
causes, typically affecting the young, and often pro-
gressing to chronic deterioration. In France, Morel
3
referred to such cases as démence précoce, while in
Scotland, Clouston
4 coined the term “adolescent insan-
ity.” In Germany, Kahlbaum
5 delineated the catatonic
syndrome, and his disciple Hecker
6 described hebephre-
nia. However, it was Emil Kraepelin (1856-1926) who
proposed to integrate those varied clinical pictures into
a single nosological entity under the name of “dementia
praecox,” based on his longitudinal observations of a
large number of clinical cases exhibiting a common pat-
tern of course which ultimately resulted in severe cog-
nitive and behavioral decline. Elaborating on the
description of the disorder in successive editions of his
Textbook,
7,8 Kraepelin acknowledged the diversity of the
clinical pictures subsumed under dementia praecox and
articulated nine different “clinical forms“ (Table I).
Although the core features of the disorder could not
always be identified reliably in the cross-section of the
clinical presentation, Kraepelin emphasised that “we
meet everywhere the same fundamental disorders in the
different forms of dementia praecox [...] in very varied
conjunctions, even though the clinical picture may
appear at first sight ever so divergent. ”
8 The “funda-
mental disorders“ which supported the concept of the
disease entity were cognitive deficit (a “general decay of
mental efficiency”) and executive dysfunction (“loss of
mastery over volitional action”), most clearly manifested
in the residual, “terminal states“ of the illness. Kraepelin
was reluctant to impute etiological significance to the
clinical variants he described, and regarded the issue of
a unitary process versus multiple disease states within
dementia praecox “an open question.” His approach to
the definition and classification of psychiatric disorders
was, essentially, based on comprehensive clinical obser-
vations and naturalistic descriptions of a large number
of individual cases. Kraepelin never issued a definitive
list of diagnostic criteria for dementia praecox and was
particularly careful to avoid claims about any “pathog-
nomonic” symptoms.The ultimate validation of the dis-
ease entity, Kraepelin believed, would come from neu-
ropathology, physiology, and biological chemistry of the
brain, whereas the specific contribution of clinical
research consisted in identifying replicable patterns of
intercorrelations between symptoms, course, and out-
come.
Kraepelin’s views on the typology of mental disorders—
often quoted, occasionally misquoted, and still
debated—continue to frame much of the present-day
psychiatric discourse. It looks indeed as if “psychiatry
still lives in a Kraepelinian world,” 
9 but the exact con-
tours of its map often get blurred. Towards the end of his
career Kraepelin experienced doubts about the valid-
State of the art
272
PAGES_DCNS 46_5.qxd:DCNS#45  9/09/10  9:39  Page 272ity of his original formulation of the nosology of psy-
choses and, in a seminal paper published in 1920, he con-
ceded that “our formulation of the problem may be
incorrect.” 
10 He considered abandoning the categorical
disease notions of schizophrenia and manic-depressive
disorder, and replacing them with a sort of dimensional
model in which schizophrenic and affective syndromes
“do not represent the expression of particular patho-
logical processes, but rather indicate the areas of our
personality in which these processes unfold.” 
10The role
of “hereditary factors” was to “make certain areas more
susceptible and accessible to pathological stimuli.”
According to Kraepelin, “the various syndromes of ill-
ness may be compared with the different registers of an
organ, any of which may be brought into play according
to the severity or extent of the pathological changes
involved. They impart a characteristic tone to the illness
quite irrespective of the mechanism which has brought
them into play.” He introduced a notion of phylogenet-
ically preformed templates of brain responses that could
be released by a variety of morbid processes—an idea
with obvious links to Hughlings Jackson’s theory of the
dissolution of higher cortical functions.
11 Kraepelin pro-
posed three hierarchically structured “registers” of psy-
chopathology—affective, schizophrenic, and encephalo-
pathic—which could recombine in different ways to
produce the manifold syndromes of the major mental
disordres.  
Bleuler’s “group of schizophrenias”
Eugen Bleuler (1857-1939) significantly modified
Kraepelin’s original concept by adding to its scope clin-
ical illnesses which did not evolve into the kind of “ter-
minal state” of deterioration, considered by Kraepelin to
be the hallmark of the disease. Having coined the term
“schizophrenia“ to replace dementia praecox, Bleuler
12
stated that schizophrenia “is not a disease in the strict
sense, but appears to be a group of diseases […]
Therefore we should speak of schizophrenias in the
plural.” Importantly, Bleuler introduced a fundamental
distinction between basic (obligatory) and accessory (sup-
plementary) symptoms of the disorder. While the acces-
sory symptoms comprised the delusions and hallucina-
tions that today are commonly classified as “positive”
symptoms, the basic symptoms included thought and
speech derailment (“loosening of associations”), voli-
tional indeterminacy (“ambivalence”), affective incon-
gruence, and withdrawal from reality (“autism”). It was
the presence of the basic symptoms that, according to
Bleuler, gave schizophrenia its distinctive diagnostic pro-
file. He acknowledged that the clinical subgroups of para-
noid schizophrenia, catatonia, hebephrenia, and simple
schizophrenia were not “natural” nosological entities and
argued that “schizophrenia must be a much broader con-
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￿ Dementia praecox simplex 
(“Impoverishment and devastation of the whole psychic life which 
is accomplished quite imperceptibly”)
￿ Hebephrenia
(Insidious change of personality with shallow capricious affect, 
senseless and incoherent behaviour, poverty of thought, occasional 
hallucinations and fragmentary delusions, progressing to profound 
dementia)
￿ Depressive dementia praecox (simple and delusional form)
(Initial state of depression followed by slowly progressive cognitive 
decline and avolition, with or without hypochondriacal or 
persecutory delusions) 
￿ Circular dementia praecox
(Prodromal depression followed by gradual onset of auditory 
hallucinations, delusions, marked fluctuations of mood and 
aimless impulsivity)
￿ Agitated dementia praecox
(Acute onset, perplexity or exaltation, multimodal hallucinations, 
fantastic delusions)
￿ Periodic dementia praecox
(Recurrent acute, brief episodes of confused excitement with 
remissions)
￿ Catatonia
(“Conjunction of peculiar excitement with catatonic stupor 
dominates the clinical picture” in this form, but catatonic 
phenomena frequently occur in otherwise wholly different 
presentations of dementia praecox)
￿ Paranoid dementia (mild and severe form)
(The essential symptoms are delusions and hallucinations. 
The severe form results in a “peculiar disintegration of psychic life”,
involving especially emotional and volitional disorders. The mild 
form is a very slowly evolving “paranoid or hallucinatory 
weak-mindedness” which “makes it possible for the patient for 
a long time still to live as an apparently healthy individual”) 
￿ Schizophasia (confusional speech dementia praecox)
(Cases meeting the general description of dementia praecox but 
resulting in an end state of “an unusually striking disorder of 
expression in speech, with relatively little impairment of the 
remaining psychic activities”)
Table I. Emil Kraepelin’s “clinical forms.”
7,8
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with the “latent” schizophrenias, which presented atten-
uated forms of the basic symptoms, manifesting as aber-
rant personality traits, he also listed within the “broader
concept” atypical depressive or manic states, Wernicke’s
motility psychoses, reactive psychoses, and other nonor-
ganic, nonaffective psychotic disorders as belonging to
the group of schizophrenias, on grounds that “this is
important for the studies of heredity,” thus foreshadow-
ing the notion of schizophrenia spectrum disorders.
Post-Kraepelinian and post-Bleulerian subtypes and
dichotomies
During the ensuing decades, a number of European and
American clinicians proposed further subnosological dis-
tinctions within the widening phenotype of schizophre-
nia, including schizoaffective disorder,
13 schizophreniform
psychoses,
14 process-nonprocess,
15 and paranoid–non-
paranoid schizophrenia.
16 Schneider
17 claimed that nine
groups of psychotic manifestations, designated as “first-
rank symptoms” (FRS), had a “decisive weight” in the
diagnosis of schizophrenia: audible thoughts; voices argu-
ing about, or discussing, the patient; voices commenting
on the patient’s actions; experiences of influences on the
body; thought withdrawal and other interference with
thought; thought broadcast (diffusion of thought); delu-
sional perception; and other experiences involving
“made” impulses and feelings experienced as caused by
an outside agency. Due to the sharpness of their defini-
tion and the hope that they could be reliably ascertained,
the FRS were subsequently incorporated in the Research
Diagnostic Criteria, RDC,
18 DSM-III,
19 and ICD-10.
20The
Catego algorithm,
21 used in the WHO cross-national stud-
ies, defined a “nuclear” schizophrenia (S+) characterized
by presence of at least 3 out of 6 FRS. Familiality and
modest to substantial heritability has been reported for
the FRS,
22 but a recent study
23 found that these symptoms
did not predict severe deterioration and cognitive deficit
in schizophrenia patients.
Leonhard’s alternative classification of the 
“endogenous” psychoses
In a clinical tradition aiming to group psychotic illnesses
on the basis of presumed localized cerebral dysfunction,
Karl Leonhard
24 developed an elaborate classification of
the “endogenous” psychoses which departed substan-
tially from the Kraepelinian and Bleulerian nosology.
Leonhard defined sharply delineated disease entities,
described by a detailed psychopathology emphasizing
objective signs (eg, psychomotor behavior), course and
outcome, and family history. The nonaffective psychoses
were split into “systematic” and “unsystematic” groups
of schizophrenias, and a third group of “cycloid” psy-
choses, each containing further subtypes (Table II), for
which Leonhard claimed distinct categorical disease sta-
tus. While the “unsystematic” schizophrenias were con-
sidered to be primarily genetic, hereditary factors were
thought to play a secondary role in the cycloid psychoses
and the “systematic” schizophrenias, which were pre-
sumed to be exogenously determined, eg, by maternal
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I.  Group of systematic schizophrenias (Insidious onset, auditory and somatic hallucinations, delusions, early blunting of affect, continuous 
unremitting course, personality deterioration)
Paraphrenias (Auditory hallucinosis, audible thoughts, thought broadcast, passivity experiences, delusional misidentifications, falsifications 
of memory)
Hebephrenias (Extreme autistic withdrawal, flat affect, impoverished or disorganized speech and behaviour)
Catatonias (Excessive parakinesias, mannerisms, verbigeration, posturing, stereotypies, mutism, auditory hallucinations)
II.  Group of unsystematic (atypical) schizophrenias (Rapid onset, relatively preserved affect, remitting course, mild personality deterioration)
Affect-laden paraphrenia (Paranoid delusions with affective loading)
Cataphasia (schizophasia) (Incoherent, pressured speech but well-organised behaviour)
Periodic catatonia (Episodic hyper- or hypokinesia, mixed excitatory and hallucinatory symptoms)
III.  Group of cycloid psychoses (Sudden onset, pervasive delusional mood, multimodal hallucinations, labile affect, polarity of manifestations, 
typically complete recovery from episode)
Anxiety-happiness psychosis (Extreme shifts of affect, polarity intense fear – ecstatic elation)
Motility psychosis (Impulsive hypermotility – psychomotor inhibition)
Confusion psychosis (Incoherent pressure of speech – mutism)
Table II. Karl Leonhard’s classification of the non-affective endogenous psychoses.
24
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ing. Notably, Leonhard’s classification neither expands,
nor constricts, the outer boundaries of schizophrenia, but
carves up the schizophrenia spectrum in a different way.
The notion of a schizophrenia spectrum
The concept of a continuum or spectrum of schizo-
phrenia-related phenotypes originates in the observa-
tion that several ostensibly different disorders tend to
cluster among biological relatives of individuals with
clinical schizophrenia.
25 Epidemiological and family
studies suggest that the genetic liability to schizophre-
nia is shared with liability to other related syndromes.
26,27
The term “schizotypy,” first introduced by Rado
28 and
Meehl,
29 describes a personality characterized by anhe-
donia, ambivalence, “interpersonal aversiveness,” body
image distortion, “cognitive slippage, “and sensory,
kinesthetic, or vestibular aberrations. Chapman et al
30
designed scales to measure perceptual aberrations and
“magical ideation” as traits predicting “psychosis prone-
ness.” These constructs were later amalgamated with
clinical descriptions from the Danish-US adoptive study
into the DSM-III diagnostic category of schizotypal per-
sonality disorder (SPD), which is now central to the
spectrum notion.
31 The frequent occurrence of SPD
among first-degree relatives of probands with schizo-
phrenia has been replicated in the Roscommon epi-
demiological study,
32 which added to the schizophrenia
spectrum further disorders cosegregating within fami-
lies. The resulting “continuum of liability“ includes: (i)
“typical“ schizophrenia; (ii) schizotypal and paranoid
personality disorders; (iii) schizoaffective disorder,
depressed type; (iv) other nonaffective psychotic disor-
ders (schizophreniform, atypical psychosis); and (v) psy-
chotic affective disorders. In all its variations, the spec-
trum concept remains critically dependent on the
validity of the SPD concept. Accumulating evidence
from family and twin data indicates that SPD is multi-
dimensional and may be genetically heterogeneous.
33-35
Its manifestations fall into two genetically independent
clusters: a “negative” cluster (odd speech and behavior,
inappropriate affect, and social withdrawal), more com-
mon among relatives of schizophrenic probands, and a
“positive” cluster (magical ideation, brief quasipsychotic
episodes), associated with increased incidence of affec-
tive disorders in relatives. “Negative“ schizotypy may
indeed represent a subclinical forme fruste of schizo-
phrenia, manifesting attenuated cognitive deficits and
brain structural abnormalities. 
Positive-negative schizophrenia (“Type I” and 
“Type II”)
A general “weakening” of mental processes resulting in
a “defect” was the cornerstone of Kraepelin’s dementia
praecox, who suggested that precursors of “defect” could
be detected early in the illness, coexisting with “produc-
tive” or “florid” symptoms.
8 Since the 1970s, the terms
“defect” and “productive” symptoms have been virtually
replaced by “negative“ and “positive“ symptoms.” 
36
Crow
37 proposed a simple subclassification of schizo-
phrenia, based on the predominance of either positive
or negative symptomatology. “Type I” (positive) schizo-
phrenia was characterized by hallucinations, delusions,
and formal thought disorder, with a presumed underly-
ing dopaminergic dysfunction, while patients with “Type
II” (negative) schizophrenia displayed social withdrawal,
loss of volition, affective flattening, and poverty of
speech, presumed to be associated with structural brain
abnormalities. Criteria and rating scales for positive
(SAPS) and negative (SANS) schizophrenia were pro-
posed by Andreasen and Olsen.
38 The initial typology,
implying discrete, mutually exclusive “types,” was later
replaced by a negative and a positive dimension, allow-
ing the two kinds of symptoms to co-occur in the same
individual.
39
Deficit–nondeficit schizophrenia
Carpenter and collaborators
40,41 proposed the delineation
of a subtype of schizophrenia characterized by enduring
“primary” negative symptoms that could not be con-
strued as sequelae of other psychopathology (Table III).
This clinical construct, evocative of Kraepelin’s demen-
tia praecox, was termed “deficit schizophrenia” (DS) and
hypothesized to be an etiologically distinct “disease”
within the schizophrenia spectrum.
42 Studies comparing
DS cases with “nondeficit” (NDS) patients and controls,
estimated the prevalence of the DS subtype at 16.5% in
unselected epidemiological samples of schizophrenia
cases and 25% to 30% within samples of chronic schiz-
ophrenia. DS and NDS do not differ on age at onset and
length of illness, which argues against a progression lead-
ing from NDS to DS. Limited support for the DS con-
struct has been provided by neuropsychological studies
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43-46The overall
pattern has been interpreted as indicative of a fronto-
temporo-parietal dysfunction, against a background of
a more global impairment. 
Statistically derived symptom dimensions or clusters
Factor analysis and related methods reduce any corre-
lations present within the data matrix to covariances of
a small number of latent factors which account for the
interrelationships among the primary variables and
explain a proportion of their variance. Based on a rela-
tively small number of input variables (SANS/SAPS
scores), a three-factor structure has been proposed
47 and
subsequently replicated.
48-50 In this model, negative symp-
toms load on a single factor of “psychomotor poverty,”
while positive symptoms split into a delusions-and-
hallucinations factor (“reality distortion”) and a
thought-and-speech disorder factor (“disorganization”).
The model has been shown to be stable and replicable
in non-European populations.
51,52 The output of factor
analyses of symptomatology depends strongly on the
content of the input - studies using SANS and SAPS
result in different solutions from those based on scales
such as the Positive and Negative Symptom Scale
(PANSS), Brief Psychiatric Rating Scale (BPRS), or
Operational Criteria Checklist (OPCRIT). In a large
sample of schizophrenia probands, McGrath et al
53 iden-
tified 5 factors (positive, negative, disorganized, affective,
and early onset/developmental) associated with risk of
psychoses and affective disorders in relatives. In a series
of factor analyses based on an expanded list of 64 psy-
chopathological symptoms, Cuesta and  Peralta
54 con-
cluded that a hierarchical 10-dimensional model pro-
vided the best fit on statistical and clinical grounds.
Factor solutions, therefore, are not unique and the ques-
tion “how many factors parsimoniously describe the
symptomatology of schizophrenia?” can only be
answered in the context of the particular selection of
symptoms and measurement methods. Therefore, factor-
analytical studies suggesting “established” dimensions
or syndromes of schizophrenia should be viewed with
caution, considering the diversity of clinical populations
and the limitations of the instruments used to generate
the input data. 
Whereas factor analysis groups variables, cluster analy-
sis groups individuals on the basis of maximum shared
characteristics. Farmer et al
55 identified two clusters into
which patients with schizophrenia could be fitted, based
on scores of 20 symptom and history items: one charac-
terized by good premorbid adjustment, later onset, and
well organized delusions, and another including early
onset, poor premorbid functioning, incoherent speech,
bizarre behavior, and family history of schizophrenia.
Using PANSS, Dollfus et al
56 obtained 4 quite different
clusters, corresponding to positive, negative, disorga-
nized, and mixed symptomatology. Thus, cluster analysis
is as dependent on the selection of input variables as fac-
tor analysis. 
Latent class analysis (LCA) assumes the existence of a
finite number of mutually exclusive and jointly exhaus-
tive groups of individuals. A latent class typology of
schizophrenia, proposed by Sham et al,
57 using data on
447 patients with nonaffective psychoses, suggested three
subgroups: a “neurodevelopmental“ subtype resembling
the hebephrenic form of the disorder (poor premorbid
adjustment, early onset, prominent negative and disor-
ganized features); a “paranoid“ subtype (less severe, bet-
ter outcome); and a “schizoaffective“ subtype (dysphoric
symptoms). In an epidemiological sample of 343
probands with schizophrenia and affective disorders,
Kendler et al
58 found 6 latent classes, broadly corre-
sponding to the nosological forms of “Kraepelinian“
schizophrenia: major depression, schizophreniform dis-
order, schizoaffective disorder (manic), schizoaffective
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1.  At least 2 of the following 6 negative symptoms must be 
present: 
Restricted affect
Diminished emotional range
Poverty of speech
Curbing of interests
Diminished sense of purpose
Diminished social drive
2.  Some combination of 2 or more of the above negative 
symptoms have been present for the preceding 12 months 
and always present during periods of clinical stability.
3. The negative symptoms are primary, ie, not secondary to factors 
other than the disease process, eg,
Anxiety
Drug effects
Suspiciousness or other psychotic symptoms
Mental retardation
Depression
4.  The patient meets DSM-III criteria for schizophrenia
Table III. Diagnostic criteria for the deficit syndrome of schizophrenia.
40,41
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using a combination of principal component analysis and
LCA in an epidemiologically ascertained sample of 387
patients with psychoses have been reported by Murray
et al.
59 In contrast to conventional LCA, a form of latent
structure analysis, known as grade of membership
(GoM), allows individuals to be members of more than
one disease class and represents the latent groups as
“fuzzy sets.” 
60,61The GoM model simultaneously extracts
from the data matrix a number of latent “pure types”
and assigns to each individual a set of numerical weights
quantifying the degree to which that individual resem-
bles each one of the identified pure types. When applied
to the symptom profiles of 1065 cases in the WHO
International Pilot Study of Schizophrenia,
62 the method
identified 8 pure types of which 5 were related to schiz-
ophrenia, 2 to affective disorders, and 1 to patients in
remission, all showing significant associations with
course and outcome variables used as external valida-
tors. 
Familial–sporadic schizophrenia
Subtyping schizophrenia by the presence/absence of a
positive family history for schizophrenia spectrum dis-
orders was proposed as a strategy expected to be more
successful in resolving heterogeneity than symptom-
based typologies.
63 Familial (F) cases are usually
defined as having ≥1 affected first-degree relative,
while sporadic (S) cases have no affected first- or sec-
ond-degree relatives. The F/S dichotomy rests on the
assumption that familial aggregation is primarily of a
genetic origin, while sporadic cases result from envi-
ronmental insults (eg, maternal obstetric complica-
tions) or de novo somatic mutations. In the majority of
studies using this classification, the proportion of famil-
ial cases was in the range of 8% to 15%. Since the F/S
subtypes were hypothesized to differ etiologically, a
number of studies, mostly of small to moderate sample
size (<100), compared the phenotypic characteristics of
the two groups
64,65 but found no significant differences
in age at onset, symptom patterns, severity, treatment
response and outcome, and the findings regarding
obstetric complications are inconclusive.
66 By and large,
the F/S classification has not so far identified homoge-
neous groups for genetic research, possibly due to the
likely presence of unexpressed genotypes in schizo-
phrenia families.
67
The present diagnostic classifications: 
DSM-IV and ICD-10
While European psychiatry rarely departed in a signifi-
cant way from the nosological concepts formulated by
Kraepelin and his followers, the practically undisputed
dominance of psychodynamic psychiatry in North
America over many decades came to an end with the
“neo-Kraepelinian revolution” of the 1970s.
68The devel-
opment of operational diagnostic criteria,
69,70 which were
presumed to reflect the Kraepelinian categorical nosol-
ogy, and their incorporation in the Third Edition of the
Diagnostic and Statistical Manual of the American
Psychiatric Association, DSM-III,
19 was a turning point
in the conceptualization of psychiatric disorders in gen-
eral and of schizophrenia in particular. The likely gains
in the reliability and reproducibility of diagnostic assess-
ment based on explicit rules and criteria led to the adop-
tion of a similar approach in the mental disorders chap-
ter of the 10th revision of the World Health
Organization’s International Classification of Diseases,
ICD-10,
20 which in turn provided a stimulus for the
development of DSM-IV.
71 The diagnostic criteria of
ICD-10 and DSM-IV were originally conceived with a
view to achieving three fundamentally different goals:
(i) to identify groups of patients with broadly similar
clinical presentation and prognosis; (ii) to facilitate early
diagnosis and choice of treatment; and (iii) to define a
homogeneous heritable diagnostic category for genetic
and other aetiological research.
72While the the first two
goals have, by and large, been achieved as regards clin-
ical utility of the criteria, attainment of the third goal
remains remote. 
There are both similarities and differences in the way the
two classifications define schizophrenia. In contrast to
DSM-IV, which provides a single set of “operational”
diagnostic criteria for all users, ICD-10 was designed as
a “family” of inter-related versions addressing different
users. While the ICD-10 volume Clinical Descriptions
and Diagnostic Guidelines is the conceptual “core” of the
system, the ICD-10 Diagnostic Criteria for Research and
the WHO Guide to Mental Health in Primary Care are
derivatives for use in specific context.
72A comparison of
the two sets of diagnostic criteria (in an abridged for-
mat) is provided in Tables IV and V.
While the opening of the glossary definition in ICD-10
is an explicit acknowledgement of Bleuler’s point that
“schizophrenia” is in fact a group of disorders, the DSM-IV
Diagnostic concept of schizophrenia - Jablensky Dialogues in Clinical Neuroscience - Vol 12 . No. 3 . 2010
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Both sets of criteria refer to (i) characteristic symptoms
present in the cross-section of the clinical picture,
weighted differentially for diagnostic significance (“at
least one…” or “two or more…”); (ii) the duration of
symptoms required for a reliable ascertainment; and (iii)
the longitudinal pattern of course. Both systems require
presence of “active phase” diagnostic symptoms for at
least 1 month. However, ICD-10 lays greater emphasis
on the Schneiderian first-rank symptoms than does
DSM-IV. An important difference between the two clas-
sifications is the DSM-IV requirement of at least 6
months, duration of any disturbances (including pro-
dromal and residual symptoms) for a confident diagno-
sis to be made, which relegates cases of shorter duration
to a provisional diagnosis of schizophreniform disorder.
This requirement is absent in ICD-10, where it was con-
sidered that a period of 4 weeks is long enough to elim-
inate the majority of acute nonschizophrenic psychoses
associated with substance use. Another major difference
between the two classifications is related to the DSM-IV
Criterion B requiring the presence of social or occupa-
tional dysfunction as part of the definition of schizo-
phrenia. The explicit assumption, applied throughout all
diagnoses of ICD-10, is that social and occupational
functioning is context-dependent and not an invariant
attribute of the clinical syndrome. It is widely assumed,
though not empirically demonstrated, that in compari-
son with ICD-10, the DSM-IV criteria of at least 6
months' duration and social/ocupational dysfunction tip
the scales towards more severe or chronic illness. 
Overall, both DSM-IV and ICD-10 have promoted bet-
ter diagnostic agreement and improved communication,
including statistical reporting on morbidity, services,
treatment, and outcomes. The reliability of psychiatrists’
diagnosis of schizophrenia and related disorders has
been improved, at least in research settings in which
structured interviews were used, incorporating explicit
definitions, criteria, and decision rules. However, such
improvements in relaibility have shifted attention to the
more fundamental problem of the validity of the diag-
nostic concepts of schizophrenia incorportated in cur-
rent classifications.
72
The vexing issue of validity versus utility
There is no single agreed meaning of validity in science,
although it is generally accepted that the concept
addresses “the nature of reality.” 
73 Psychologists gener-
ally adopt the distinction between content, criterion-
related, and construct validity, and their main concern
has been with the validity of psychological tests.
Borrowing terminology from psychometric theory, psy-
chiatrists have mainly been concerned with concurrent
and predictive validity, partly because of their relevance
to the issue of the validity of diagnoses. The ability to
predict outcome, both in the absence of treatment and
in response to specific therapies, has always been a cru-
cial function both of physicians and of their diagnoses.
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Robins and Guze
74 proposed several formal criteria for
establishing the validity of psychiatric diagnoses: (i) clin-
ical description; (ii) laboratory studies; (iii) delimitation
from other disorders; (iv) follow-up studies (including
evidence of diagnostic stability); and (v) family studies.
This schema was elaborated by Kendler
75 who distin-
guished between antecedent validators (familial aggre-
gation, premorbid personality and precipitating factors);
concurrent validators (including psychological tests); and
predictive validators (diagnostic consistency over time,
rates of relapse and recovery, and response to treat-
ment). Andreasen
76 has proposed “a second structural
program for validating psychiatric diagnosis” and listed
several additional validators–molecular genetics and
molecular biology, neurochemistry, neuroanatomy, neu-
rophysiology and cognitive neuroscience—all potentially
capable of linking symptoms and diagnoses to their
neural substrates.
The problem with both Robins and Guze’s and
Kendler’s validity criteria is that they implicitly assumed
that psychiatric disorders were discrete entities. The pos-
sibility that disorders might merge into one another with
no natural boundary (or “point of rarity”)
77 was not con-
sidered. Robins and Guze’s classical paper was written
at a time when it was assumed that schizophrenia and
bipolar disorder were transmitted by a single, or at the
most by a small number of genes. The present situation
is different. It is now almost generally accepted that
many different genes and gene networks contribute to
the etiology of most of psychiatry’s major syndromes,
including schizophrenia, and that combinations of such
genes are risk factors for what have until now been
regarded as unrelated syndromes. For example, the
microdeletion in chromosome 22q11 which underlies the
velocardiofacial syndrome is associated with a raised
incidence of intellectual disability, schizophrenia, and
bipolar affective disorder.
78,79 The genetic basis of schiz-
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orders, including schizotypal personality disorder and,
possibly, bipolar disorder with psychotic symptoms.
2 It
will not be surprising if such findings of overlapping
genetic predisposition to seemingly unrelated disorders
become soon the rule rather than the exception. 
Against this background, a recent review of the evidence
for assessing schizophrenia and related psychotic disor-
ders against a range of “validating criteria” proposed by
the DSM-V Task Force Study Group
80 is worth high-
lighting. The examined criteria included: (i) shared
genetic risk factors and familiality; (ii) environmental
risk factors and gene-environment interactions; (iii)
shared neural substrates; (iv) shared biomarkers; (v)
shared temperamental antecedents; (vi) shared cogitive
and emotional processing abnormalities; (vii) comor-
bidity among disorders; (viii) course of illness; and (ix)
treatment response. The authors concluded that “there
is insufficient evidence of the etiology and pathophysi-
ology to base group membership on causality.”
Furthermore, they felt that “in-depth phenomenology
and pattern of illness are not examined in most studies,”
and that “it is not known whether the spectrum criteria
would support the DSM-IV cluster of schizophrenia and
related disorders.” 
80
There are several reasons why the crucial issue here is
whether clear boundaries or qualitative differences exist
at the level of the defining characteristic of the syn-
drome, rather than understanding of etiology. In the
first place, understanding of etiology is not an all or
none issue that can be resolved once and forever—it is
a long-term process, with knowledge emerging in stages
as a complex network of interacting events is eluci-
dated. The consequence of defining diagnostic validity
first in terms of the presence (or absence) of continu-
ities and discontinuities at the level of manifest clinical
syndromes is that most contemporary psychiatric dis-
orders, including schizophrenia with a pedigree stretch-
ing back to the 19th century, cannot yet be described as
valid disease categories. This does not mean, however,
that they are not valuable concepts, and it is crucial to
maintain a clear distinction between validity and utility.
At present, these two terms are often used as if they
were synonyms.
Many, though not all, of the diagnostic concepts repre-
sented by the categories of disorder listed in contempo-
rary classifications like DSM-IV and  ICD-10 are
extremely useful to practising clinicians, and most would
be hard put to cope without them. Diagnostic categories
provide invaluable information about the likelihood of
future recovery, relapse, deterioration, and social hand-
icap; they guide decisions about treatment; and they pro-
vide a wealth of information about similar patients
encountered in clinical populations or community sur-
veys throughout the world—their frequency and demo-
graphic characteristics, their family backgrounds and
premorbid personalities, their symptomatology and its
evolution over time; the results of clinical trials of sev-
eral alternative therapies; and research into the etiology
of the syndrome.
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Categories and/or dimensions?
There are many different ways in which classifications
can be constructed. The fundamental choice is between
a categorical and a dimensional structure, and it is worth
recalling the observation by the philosopher Carl
Hempel
81 that, although most sciences start with a cate-
gorical classification of their subject matter, they often
replace this with dimensions as more accurate measure-
ment becomes possible. The requirement that the cate-
gories of a typology should be mutually exclusive and
jointly exhaustive has never been fully met by any psy-
chiatric classification. Medical, including psychiatric, clas-
sifications are eclectic in the sense that they are orga-
nized according to several different classes of criteria
(eg, causes, presenting symptoms or traits, age at onset,
course), without a clear hierarchical arrangement. One
or the other among them may gain prominence as
knowledge progresses or conditions change. However,
despite their apparent logical inconsistency, medical clas-
sifications survive and evolve because of their essentially
pragmatic nature. Their utility is tested almost daily in
clinical or public health decision-making, and this
ensures a natural selection of useful concepts by weed-
ing out impracticable or obsolete ideas.
Categorical typologies are the traditional, firmly
entrenched form of representation for medical diag-
noses. As such, they have many practical and conceptual
advantages. They are thoroughly familiar, and most
knowledge of the causes, presentation, treatment and
prognosis of mental disorder was obtained, and is
stored, in relation to these categories. They are easy to
use under conditions of incomplete information; and
they have a capacity to “restore the unity of the
patient’s pathology by integrating seemingly diverse ele-
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82 The
principal disadvantage of the categorical model is its
propensity to encourage a “discrete entity” view of the
nature of psychiatric disorders, ignoring the evidence
that diagnostic categories do not necessarily represent
discrete entities. Dimensional models, on the other
hand, have the conceptual advantage of introducing
explicitly quantitative variation and graded transition
between forms of disorder, as well as between “nor-
mality” and pathology. This is important for classifying
patients who fulfill the criteria for two or more cate-
gories of disorder simultaneously, or who straddle the
boundary between two adjacent syndromes. Whether
schizophrenia can be better described dimensionally or
categorically remains an open, researchable question.
83
The difficulties with dimensional models stem from
their novelty; lack of agreement on the number and
nature of the dimensions required to account ade-
quately for clinically relevant variation; the absence of
an established, empirically grounded metric for evalu-
ating severity or change; and, perhaps most importantly,
the complexity and cumbersomeness of dimensional
models in everyday clinical practice. In the instance of
schizophrenia, the majority of dimensional models that
have been proposed to date build upon well-known fac-
tor-analysis models grouping into factorial dimension
symptoms, typically assessed using rating scales with
predetermined sections assessing “positive” “negative,”
“disorganization,” and “affective” disorders. The pro-
posed dimensions usually involve the assignment of
some sort of a rank scale with arbitrarily assigned scores
of presence/absence and severity (“more” or “less”).
Clearly, such crude measures fail to do justice to the
descriptive psychopathology and phenomenology of
psychotic experience which aims to discern meaningful
qualitative distinctions within symptom domains—eg,
the differences between primary and secondary
explanatory delusions, or between common second-per-
son auditory hallucinations and voices experienced as
coming from one’s own body. 
These considerations seem to preclude, at least for the
time being, a radical restructuring of psychiatric classifi-
cation from a predominantly categorical to a predomi-
nantly dimensional model. Moreover, categorical and
dimensional models need not be mutually exclusive, as
demonstrated by so-called mixed or class-quantitative
models
84 which combine qualitative categories with
quantitative trait measurements. For example, there is
increasing empirical evidence that should make it attrac-
tive to supplement a retained (and refined) categorical
clinical description of the syndrome of schizophrenia
with selected quantitative traits such as attention or
memory dysfunction and volumetric deviance of cere-
bral structures.
Endophenotypes in schizophrenia
Amidst growing doubts in the capacity of the broad
diagnostic category to serve as a reliable phenotype for
gene discovery,
85 the concept of endophenotypes (inter-
mediate, elementary, alternative, or correlated pheno-
types) offered a novel perspective on subtyping schizo-
phrenia that could be either an alternative or a
complement to symptom-based phenotypes. The term
was introduced into schizophrenia genetics by
Gottesman and Shields.
86As “measurable components
unseen by the unaided eye along the pathway between
disease and distal genotype,”
87 endophenotypes are
expected to be: (i) associated with the clinical disorder
but not part of its diagnosis; (ii) heritable; (iii) state-inde-
pendent (ie, present before the onset of active illness or
during remissions); (iv) cosegregating with illness in fam-
ilies; and (v) found in unaffected family members at a
higher rate than in the general population.
88 Earlier
expectations, eg, that endophenotypes would have a sim-
pler genetic architecture, now appear as unrealistic. An
important requirement, however, is that an endopheno-
type should be a represented by a quantitatively mea-
surable trait. In schizophrenia research, an increasing
number of endophenotypes, mainly related to psy-
chophysiological, brain imaging, and cognitive measures,
are being explored (Table VI).
Cognitive dysfunction as an endophenotype
Cognitive deficits are now widely accepted as a core fea-
ture of schizophrenia, rather than an epiphenomenon of
the illness state.
89,90 Deficits in multiple cognitive
domains predate the onset of clinical symptoms
91-93; are
not attributable to antipsychotic medications
94; persist
over the course of the illness and are unrelated to its
duration
95,96; and represent a stable trait.
97 Pervasive cog-
nitive dysfunction has been reported in >50% of schiz-
ophrenia patients,
98 and there is compelling evidence
that cognitive deficits are significantly correlated with
impairments in activities of daily living (ADL),
99,100 but
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101
Population-based cohort studies
102,103 have found that
compromised general cognitive ability in late adoles-
cence is a strong predictor of subsequent schizophrenia
risk. Family studies indicate that a proportion of the
unaffected first-degree relatives of index cases of schiz-
ophrenia display similar patterns of deficit in an atten-
uated form.
104-106 The balance of evidence suggests that
cognitive dysfunction meets most of the criteria of an
endophenotype in schizophrenia. This is underscored by
the meta-analysis by Heinrichs and Zakzanis
107 of 204
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Neurophysiological markers and endophenotypes
Electrodermal deviance
Prepulse inhibition of the startle reflex (PPI)
Deficient gating of the auditory evoked response (P50) 
P300 amplitude reduction and latency delay
N400 amplitude reduction (semantic context underutilization)
Mismatch negativity (MMN)
Smooth pursuit eye movement dysfunction (SPEM)
Antisaccade error rate (AS)
Multivariate electrophysiological endophenotype (MMN, P50, 
P300, AS)
Neuroimaging markers and endophenotypes
Fronto-thalamic-cerebellar gray matter deficit
Fronto-striato-thalamic gray matter deficit
MRI whole-brain non-linear pattern classification
Frontal hypoactivation in response to cognitive tasks 
(hypofrontality)
Atrophic and static (neurodevelopmental) schizophrenia 
endophenotypes
Cognitive markers and endophenotypes
Continuous performance tests (CPT, signal/noise ratio)
Attention and vigilance-based cognitive subtype
Verbal dysmnesic cognitive subtype 
Verbal memory deficit, cortical or subcortical cognitive type
Dysexecutive cognitive subtype
Prefrontal executive/working memory phenotype 
Frontal/abstraction deficit profile
Spatial working memory
Generalised (diffuse, pervasive) cognitive deficit, CD
Other markers and endophenotypes
Neurological soft signs
Composite laterality phenotype 
Nailfold plexus visibility
Minor physical anomalies
Table IV. ‘Candidate’ endophenotype markers in schizophrenia research
(reviewed in ref 72).
Schizophrenia (F20): diagnostic criteria for research
At least one... 
(a) thought echo, insertion, withdrawal or broadcasting
(b) delusions of control, influence or passivity
(c) hallucinatory voices – running commentary or discussing the 
patient
(d) persistent delusions - culturally inappropriate and completely 
impossible
Or at least two...
(a) persistent hallucinations in any modality, when accompanied 
by delusions
(b) neologisms, breaks or interpolations in the train of thought, 
incoherence
(c) catatonic behaviour
(d) ‘negative’ symptoms: apathy, paucity of speech, emotional 
blunting or incongruity
...should be present for most of the time during an episode of psy-
chotic illness lasting for at least 1 month
Pattern of course (period of observation at least 1 year)
Continuous (no remission of psychotic symptoms)
Episodic with progressive deficit (‘negative’ symptoms in the 
intervals)
Episodic with stable deficit (persistent but non-progressive 
‘negative’ symptoms)
Episodic remittent (complete remissions between psychotic  episodes)
Incomplete remission
Complete remission
Other 
Course uncertain, period of observation too short
Clinical subtypes
Paranoid
Hebephrenic
Catatonic
Undifferentiated
Post-schizophrenic depression
Residual
Simple
Other
Unspecified
Other F2 disorders
Schizotypal disorder (F21)
Persistent delusional disorders (F22)
Acute and transient psychotic disorders (F23)
Induced delusional disorder (F24)
Schizoaffective disorders (F25)
Other non-organic psychotic disorders (F28)
Unspecified non-organic psychosis (F29)
Table V. ICD-10 / F2 group of disorders.
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7420 schizophrenia patients and 5865 controls), in which
effect sizes (Cohen’s d) and the U statistic (degree of
non-overlap) were calculated for 22 neurocognitive test
variables ranging from IQ, verbal memory, and attention
to executive function and language. Although no single
test or cognitive construct was capable of separating
perfectly schizophrenia patients from normal controls,
7 measures achieved effect sizes greater than 1.0 (60-
70% non-overlap between the cases and controls): ver-
bal memory (1.41), bilateral motor skills (1.30), perfor-
mance IQ (1.26), the continuous performance task
(1.16), word fluency (1.15), the Stroop task (1.11), and
WAIS-R IQ (1.10). Although a subset of ~50% of
patients had nearly normal performance, significant cog-
nitive impairment was common in schizophrenia and
exceeded the deficits found in some neurological disor-
ders, justifying the view that “schizophrenia is a neuro-
logical disorder that manifests itself in behavior.”
107
There is, at least, a preliminary evidence that composite
cognitive endophenotypes have the capacity to identify
genetically distinct subtypes of schizophrenia.
108
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A. Two (or more) characteristic symptoms, each present for a significant portion of time during a 1-month period 
(or less if successfully treated):
(1) delusions; (2) hallucinations; (3) disorganized speech (derailment or incoherence); (4) grossly disorganized or catatonic behavior; 
(5) negative symptoms (affective flattening, alogia, or avolition). (Only one symptom is required if delusions are bizarre or hallucinations 
consist of a voice keeping up a running commentary...or two or more voices conversing with each other).
B. Social/occupational dysfunction
C. Duration: Continuous signs of the disturbance persist for at least 6 months, including at least 1 month of active-phase symptoms and may 
include periods of prodromal or residual symptoms. During prodromal or residual periods, the signs of the disturbance may be manifested 
by only negative symptoms or 2 or more Criterion A symptoms in an attenuated form (eg, odd beliefs, unusual perceptual experiences).
D. Schizoaffective and mood disorder exclusion
E. Substance/general medical condition exclusion
F. Relationship to a pervasive developmental disorder: If there is a history of Austistic Disorder or another pervasive developmental disorder, 
the additional diagnosis of Schizophrenia is made only if prominent delusions or hallucinations are also present for at least a month.    
Subtypes: 
Paranoid (295.30)
Disorganized (295.10)
Catatonic (295.20)
Undifferentiated (295.90)
Residual (295.60)
Longitudinal course:
Episodic with interepisode residual symptoms (prominent negative symptoms may be added)
Episodic with no interepisode residual symptoms
Continuous (prominent negative symptoms may be added)
Single episode in partial remission (prominent negative symptoms may be added)
Single episode in full remission
Other of unspecified pattern
Other disorders within the same group:
Schizophreniform disorder (with / without good prognostic features) (295.40)
Schizoaffective disorder (bipolar or depressive type) (295.70)
Delusional disorder (297.1)
Brief psychotic disorder (with / without stressor, or with postpartum onset) (298.8)
Shared psychotic disorder (297.3)
Psychotic disorder due to a general medical condition (293.xx)
Substance-induced psychotic disorder (291.xx or 292.xx)
Psychotic disorder not otherwise specified (298.9)
Table VI. DSM-IV-TR Schizophrenia and other psychotic disorders.
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Conclusion: the way forward
More than a century since the delineation of dementia
praecox by Kraepelin, the etiology, neuropathology, and
pathophysiology of schizophrenia remain elusive.
Despite the availability of criteria allowing reliable diag-
nostic identification, schizophrenia essentially remains a
broad clinical syndrome defined by reported subjective
experiences (symptoms), loss of function (behavioral
impairments) and variable patterns of course. Research
has identified a number of putative biological markers
associated with the disorder, including neurocognitive
dysfunction, brain dysmorphology, and neurochemical
abnormalities. Yet none of these variables has to date
been definitively proven to possess the sensitivity and
specificity expected of a diagnostic test. Genetic linkage
and association studies have targeted multiple candidate
loci and genes, but failed to demonstrate that any spe-
cific gene variant, or a combination of genes, is either
necessary or sufficient to cause schizophrenia. Thus, the
existence of a specific brain disease underlying schizo-
phrenia remains a hypothesis. 
Against a background of an ever-increasing volume of
research data, the inconclusiveness of the search for
causes of the disorder fuels doubts about the validity of
the schizophrenia construct as presently defined, some
leading to proposals to discard the category,
109 or to
replace it with a continuum of “psychosis.” 
110 Given the
protean nature of the symptoms of schizophrenia and
the poor coherence of the clinical and biological findings,
such doubts are not without reason. However, simply
dismantling the concept is unlikely to result in an alter-
native model that would account for the host of clinical
phenomena and research data consistent with a disease
hypothesis of schizophrenia. Although there are grounds
for the suspicion that schizophrenia is not a homoge-
neous entity, this has never been directly demonstrated,
mainly because few studies of the appropriate kind have
ever been undertaken. For the time being, the clinical
concept of schizophrenia is supported by empirical evi-
dence that its multiple facets form a broad syndrome
with non-negligible internal cohesion and a characteris-
tic evolution over time. The dissection of the syndrome
with the aid of endophenotypes is beginning to be per-
ceived as a promising approach in schizophrenia genet-
ics. As new concepts and data emerge from molecular
genetics, cognitive science, or brain imaging, new per-
spectives on disease causation and brain function are
likely to be on stage in the next decade. 
A recent strategic proposal about a future typology of
psychiatric disorders, linking genomics and neural cir-
cuits functioning as “hubs” for a range of phenotypes—
cutting across the present categories and joining schizo-
phrenia, autism, bipolar disorder, as well as forms of
epilepsy and intellectual disability—may be a signpost
of future developments.
111 Such research must be sup-
ported by a refined, reliable, and valid phenotyping—
not only at the level of symptoms, but increasingly
involving correlated neurobiological features. The study
of endophenotypes transcending the conventional diag-
nostic boundaries may reveal unexpected patterns of
associations with symptoms, personality traits, or behav-
ior. The mapping of clinical phenomenology on specific
brain dysfunction is now becoming feasible and the
resulting functional psychopathology may in the future
substantially recast the present nosology. ❏
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El concepto diagnóstico de la esquizofrenia:
su historia, evolución y perspectivas futuras. 
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Le concept diagnostic de la schizophrénie:
histoire, évolution et perspectives futures
Plus d’un siècle après la description de la démence
précoce par Kraepelin, l’étiologie, la neuropatho-
logie et la physiopathologie de la schizophrénie
demeurent difficiles à appréhender. Malgré la dis-
ponibilité de critères permettant une identification
diagnostique fiable, la schizophrénie reste surtout
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être perçue comme une approche prometteuse
dans la génétique de la schizophrénie.
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